Home › Urothelial (Transitional Cell) Carcinoma › Illinois › Joliet
Urothelial (Transitional Cell) Carcinoma clinical trials in Joliet, IL
3 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in and around Joliet (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- UC Comprehensive Cancer Center at Silver Cross, New Lenox · 6 mi away
- University of Chicago Medicine-Orland Park, Orland Park · 14 mi away
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
RecruitingPhase 3
- Hope and Healing Clinical Research LLC, New Lenox · 6 mi away
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RecruitingPhase 2
- University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox · 6 mi away
- The University of Chicago Medicine Center for Advanced Care Orland Park, Orland Park · 14 mi away
Urothelial (Transitional Cell) Carcinoma trials in other cities
- Nashville, TN23 studies
- New York City, NY22 studies
- Houston, TX19 studies
- Dallas, TX18 studies
- Edison, NJ18 studies
- Los Angeles, CA17 studies
- Queens, NY15 studies
- Chicago, IL14 studies
- Arlington, VA12 studies
- Boston, MA11 studies
- San Antonio, TX11 studies
- Austin, TX10 studies
Other studies in Joliet
- Lung Cancer12 studies
- Non-Small Cell Lung Cancer12 studies
- Bladder Cancer7 studies
- Metastatic Cancer7 studies
- Head and Neck Squamous Cell Carcinoma6 studies
- Prostate Cancer5 studies
- Acute Myeloid Leukemia5 studies
- Hypopharyngeal Cancer5 studies
- Laryngeal Cancer5 studies
- Oral Cancer5 studies
- Breast Cancer4 studies
- Ovarian Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.